Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (1349.HK)
1349.HK Stock Price Chart
Explore Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. interactive price chart. Choose custom timeframes to analyze 1349.HK price movements and trends.
1349.HK Company Profile
Discover essential business fundamentals and corporate details for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (1349.HK) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
13 Aug 2002
Employees
921.00
Website
https://www.fd-zj.comCEO
Da Jun Zhao
Description
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells bio-pharmaceutical products. It offers genetic engineering platform drugs, including CD30-DM1 antibody-drug conjugate (ADC), which is in Phase I clinical trials for tumors; Trop2-SN38 ADC that is in Phase I clinical trials for triple negative, breast, bladder, gastric, and other tumors; Trop2-BB05 ADC that is in pre-clinical studies for lung cancer and triple negative breast cancer; and HER2 ADC that has completed pre-clinical research for metastatic breast and gastric cancers. The company also provides photodynamic technical platform drugs, such as hemoporfin for port wine stain, which is in Phase IV clinical trial; and aminolevulinic acid, which is in Phase II clinical trials for cervical diseases infected by HPV and acne, as well as completed pre-clinical study for brain gliomas. In addition, it offers nano technical platform drugs, such as Nanoparticle Albumin-bound Paclitaxel that is in pre-clinical studies for tumors, as well as developing Doxorubicin liposome for tumors. Further, the company offers oral solid preparation technology, which includes obeticholic acid for hepatobiliary and autoimmune disease; timolol maleate cream that is in pre-clinical studies for infantile hemangioma; and FZJ-003 oral preparation, which is in Phase I clinical trials for rheumatoid arthritis, as well as in Phase II clinical trials for atopic dermatitis and ulcerative colitis. Additionally, it develops pharmaceutical and medical devices; medical diagnostic products and related services; and sells daily necessities, and clinical laboratory analysis instruments and software. It also engages in the technology development, transfer, consulting, and promotion activities; produces freeze-dried powder injections and APIs; and invests in overseas medical projects. The company was founded in 1996 and is based in Shanghai, the People's Republic of China.
1349.HK Financial Timeline
Browse a chronological timeline of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 13 Aug 2025
Dividend declared on 10 Jul 2025
A dividend of $0.03 per share was announced, adjusted to $0.03. The dividend was paid on 25 Aug 2025.
Earnings released on 28 Apr 2025
Earnings released on 28 Mar 2025
EPS came in at -$0.07 , while revenue for the quarter reached $170.80M .
Earnings released on 25 Oct 2024
EPS came in at $0.02 , while revenue for the quarter reached $155.72M .
Dividend declared on 26 Aug 2024
A dividend of $0.02 per share was announced, adjusted to $0.02. The dividend was paid on 10 Oct 2024.
Earnings released on 12 Aug 2024
EPS came in at $0.07 , while revenue for the quarter reached $279.73M , missing expectations by -68.12%.
Dividend declared on 4 Jul 2024
A dividend of $0.08 per share was announced, adjusted to $0.08. The dividend was paid on 26 Aug 2024.
Earnings released on 29 Apr 2024
EPS came in at $0.00 , while revenue for the quarter reached $159.74M , missing expectations by -81.80%.
Earnings released on 28 Mar 2024
EPS came in at $0.02 , while revenue for the quarter reached $158.02M .
Earnings released on 30 Sept 2023
EPS came in at $0.02 , while revenue for the quarter reached $198.57M .
Earnings released on 30 Jun 2023
EPS came in at $0.06 , while revenue for the quarter reached $360.85M .
Dividend declared on 5 Jun 2023
A dividend of $0.08 per share was announced, adjusted to $0.08. The dividend was paid on 25 Aug 2023.
Earnings released on 31 Mar 2023
EPS came in at $0.01 , while revenue for the quarter reached $215.91M .
Earnings released on 31 Dec 2022
EPS came in at $0.08 , while revenue for the quarter reached $358.64M .
Earnings released on 30 Sept 2022
EPS came in at $0.12 , while revenue for the quarter reached $488.85M .
Dividend declared on 5 Jul 2022
A dividend of $0.09 per share was announced, adjusted to $0.09. The dividend was paid on 26 Aug 2022.
Earnings released on 30 Jun 2022
EPS came in at -$0.05 , while revenue for the quarter reached $152.72M .
Earnings released on 31 Mar 2022
EPS came in at $0.01 , while revenue for the quarter reached $173.53M .
Earnings released on 31 Dec 2021
EPS came in at $0.12 , while revenue for the quarter reached $541.41M .
Earnings released on 30 Sept 2021
EPS came in at $0.06 , while revenue for the quarter reached $360.73M .
Earnings released on 30 Jun 2021
EPS came in at $0.07 , while revenue for the quarter reached $327.57M .
Dividend declared on 1 Jun 2021
A dividend of $0.05 per share was announced, adjusted to $0.05. The dividend was paid on 27 Aug 2021.
Earnings released on 31 Mar 2021
EPS came in at $0.01 , while revenue for the quarter reached $149.45M .
Earnings released on 31 Dec 2020
EPS came in at $0.08 , while revenue for the quarter reached $400.93M .
Earnings released on 30 Sept 2020
EPS came in at $0.06 , while revenue for the quarter reached $297.14M .
1349.HK Stock Performance
Access detailed 1349.HK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.